113 related articles for article (PubMed ID: 11738488)
1. Structure-activity relationships in platelet-activating factor (PAF). 11-From PAF-antagonism to phospholipase A(2) inhibition: syntheses and structure-activity relationships in 1-arylsulfamido-2-alkylpiperazines.
Binisti C; Assogba L; Touboul E; Mounier C; Huet J; Ombetta JE; Dong CZ; Redeuilh C; Heymans F; Godfroid JJ
Eur J Med Chem; 2001 Oct; 36(10):809-28. PubMed ID: 11738488
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships in platelet activating factor. 9. From PAF-antagonism to PLA2 inhibition.
Binisti C; Touboul E; Mounier C; Heymans F; Bon C; Godfroid JJ
J Lipid Mediat Cell Signal; 1997 Jan; 15(2):125-44. PubMed ID: 9034960
[TBL] [Abstract][Full Text] [Related]
3. A new phospholipase A2 inhibitor, unrelated to substrate analogues: kinetic characterization of the inhibition of secretory phospholipases A2 by PMS 832.
Binisti C; Mounier C; Touboul E; Heymans F; Bon C; Godfroid JJ
J Lipid Mediat Cell Signal; 1997 Jul; 16(3):171-87. PubMed ID: 9246606
[TBL] [Abstract][Full Text] [Related]
4. Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors.
Badrinarayan P; Srivani P; Narahari Sastry G
J Mol Model; 2011 Apr; 17(4):817-31. PubMed ID: 20571844
[TBL] [Abstract][Full Text] [Related]
5. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
Lamouri A; Heymans F; Tavet F; Dive G; Batt JP; Blavet N; Braquet P; Godfroid JJ
J Med Chem; 1993 Apr; 36(8):990-1000. PubMed ID: 8478911
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
Fukushi H; Mabuchi H; Itoh K; Terashita Z; Nishikawa K; Sugihara H
Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):541-50. PubMed ID: 8004699
[TBL] [Abstract][Full Text] [Related]
7. Design and modeling of new platelet-activating factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazines.
Tavet F; Lamouri A; Heymans F; Dive G; Touboul E; Blavet N; Godfroid JJ
J Lipid Mediat Cell Signal; 1997 Jan; 15(2):145-59. PubMed ID: 9034961
[TBL] [Abstract][Full Text] [Related]
8. PAF inhibitory activity of diketopiperazines: structure-activity relationships.
Shimazaki N; Shima I; Okamoto M; Yoshida K; Hemmi K; Hashimoto M
Lipids; 1991 Dec; 26(12):1175-8. PubMed ID: 1819704
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
Serradji N; Bensaid O; Martin M; Kan E; Dereuddre-Bosquet N; Redeuilh C; Huet J; Heymans F; Lamouri A; Clayette P; Dong CZ; Dormont D; Godfroid JJ
J Med Chem; 2000 Jun; 43(11):2149-54. PubMed ID: 10841793
[TBL] [Abstract][Full Text] [Related]
10. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
Tsuri T; Haga N; Matsui T; Kamata S; Kakushi H; Uchida K
Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):75-84. PubMed ID: 1605805
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
Fukushi H; Mabuchi H; Terashita Z; Nishikawa K; Sugihara H
Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):551-9. PubMed ID: 8004700
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of piperazine sulfonamide analogs as diabetic-II inhibitors and their molecular docking study.
Taha M; Irshad M; Imran S; Chigurupati S; Selvaraj M; Rahim F; Ismail NH; Nawaz F; Khan KM
Eur J Med Chem; 2017 Dec; 141():530-537. PubMed ID: 29102178
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity.
Sallem W; Serradji N; Dereuddre-Bosquet N; Dive G; Clayette P; Heymans F
Bioorg Med Chem; 2006 Dec; 14(23):7999-8013. PubMed ID: 16908170
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
Serradji N; Bensaid O; Martin M; Sallem W; Dereuddre-Bosquet N; Benmehdi H; Redeuilh C; Lamouri A; Dive G; Clayette P; Heymans F
Bioorg Med Chem; 2006 Dec; 14(23):8109-25. PubMed ID: 16893650
[TBL] [Abstract][Full Text] [Related]
15. (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
Carceller E; Almansa C; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1992 Oct; 35(22):4118-34. PubMed ID: 1433215
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological analysis of benzazol-2-yl piperazine sulfonamides as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Hofer S; Kratschmar DV; Schernthanner B; Vuorinen A; Schuster D; Odermatt A; Easmon J
Bioorg Med Chem Lett; 2013 Oct; 23(19):5397-400. PubMed ID: 23981897
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
Serradji N; Martin M; Bensaid O; Cisternino S; Rousselle C; Dereuddre-Bosquet N; Huet J; Redeuilh C; Lamouri A; Dong CZ; Clayette P; Scherrmann JM; Dormont D; Heymans F
J Med Chem; 2004 Dec; 47(25):6410-9. PubMed ID: 15566310
[TBL] [Abstract][Full Text] [Related]
18. A novel class of platelet activating factor (PAF) antagonists. II. Modification of the 2-position of the glycerol backbone of PAF-sulfonamide isosteres.
Tsuri T; Matsui T; Haga N; Kamata S; Hagishita S; Takahashi K; Kakushi H; Uchida K; Hatakeyama H; Kurosawa A
Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):85-95. PubMed ID: 1576692
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of (4-acylpyrrol-2-yl)alkanoic acids as inhibitors of the cytosolic phospholipase A2: variation of the substituents in positions 1, 3, and 5.
Lehr M
J Med Chem; 1997 Oct; 40(21):3381-92. PubMed ID: 9341913
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship studies of 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A2alpha-mediated arachidonic acid release in intact platelets: variation of the keto moiety.
Ghasemi A; Elfringhoff AS; Lehr M
J Enzyme Inhib Med Chem; 2005 Oct; 20(5):429-37. PubMed ID: 16335050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
